Literature DB >> 28633585

Lipoprotein(a)-activated immunity, insulin resistance and new-onset diabetes.

Ayşem Kaya1, Altan Onat2, Hüsniye Yüksel2, Günay Can3, Murat Yüksel4, Evin Ademoğlu5.   

Abstract

OBJECTIVES: Some evidence suggests that serum lipoprotein[Lp](a) may be inversely linked to type-2 diabetes. We aimed to determine in nondiabetic people the relationship of serum [Lp](a) with insulin resistance and new-onset diabetes (NOD).
MATERIALS AND METHODS: Population-based middle-aged adults (n = 1685) were categorized by fasting glucose and stratified to gender, having excluded prevalent diabetic subjects. NOD (n = 90) occurred over a median 5 years' follow-up.
RESULTS: Subjects that subsequently developed NOD, derived both from the normoglycemia and impaired fasting glucose (IFG) groups,were distinguished, among others, primarily by significantly elevated serum gamma glutamyltransferase, reduced Lp(a) (by 31%) and, compared to IFG, by low total cholesterol levels. Partial correlation of Lp(a) with homeostatic model assessment (HOMA) was inverse in normoglycemic men; such correlation, neutral in normoglycemic women, proved inverse in IFG (r = -0.17). Circulating Lp(a) in individuals with paired measures increased significantly (1.55-fold) in the period from baseline up to NOD. Multivariable-adjusted logistic regression analysis for NOD in combined sexes indicated independent and additive prediction by serum Lp(a), albeit inverse in direction (RR 0.84, [95%CI 0.72; 0.97]).
CONCLUSION: Lp(a) is significantly reduced in the period preceding NOD and is inversely associated with HOMA index, observations consistent with underlying autoimmune activation.

Entities:  

Keywords:  Autoimmune activation; diabetes; impaired fasting glucose; insulin resistance; lipoprotein(a); type-2

Mesh:

Substances:

Year:  2017        PMID: 28633585     DOI: 10.1080/00325481.2017.1342508

Source DB:  PubMed          Journal:  Postgrad Med        ISSN: 0032-5481            Impact factor:   3.840


  4 in total

1.  In search of a physiological function of lipoprotein(a): causality of elevated Lp(a) levels and reduced incidence of type 2 diabetes.

Authors:  Sotirios Tsimikas
Journal:  J Lipid Res       Date:  2018-04-02       Impact factor: 5.922

Review 2.  Genetics of Lipoprotein(a): Cardiovascular Disease and Future Therapy.

Authors:  Anne Langsted; Børge G Nordestgaard
Journal:  Curr Atheroscler Rep       Date:  2021-06-20       Impact factor: 5.113

3.  Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment.

Authors:  Gregory G Schwartz; Michael Szarek; Vera A Bittner; Deepak L Bhatt; Rafael Diaz; Shaun G Goodman; J Wouter Jukema; Megan Loy; Garen Manvelian; Robert Pordy; Harvey D White; Philippe Gabriel Steg
Journal:  Diabetes Care       Date:  2021-03-15       Impact factor: 19.112

4.  High lipoprotein(a) concentrations are associated with lower type 2 diabetes risk in the Chinese Han population: a large retrospective cohort study.

Authors:  Qingan Fu; Lijuan Hu; Yuan Xu; Yingping Yi; Long Jiang
Journal:  Lipids Health Dis       Date:  2021-07-27       Impact factor: 3.876

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.